Loading…
Structure Therapeutics Inc. is projected to decline to $39.38 by 2027, a -5% move from its current price of $41.25. GPCR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 6/10/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jun 11 | $40.24 | $41.25 | $42.30 | +0.01% |
| Jun 12 | $39.83 | $41.26 | $42.74 | +0.02% |
| Jun 13 | $39.52 | $41.26 | $43.08 | +0.03% |
| Jun 14 | $39.26 | $41.27 | $43.38 | +0.04% |
| Jun 15 | $39.03 | $41.27 | $43.64 | +0.05% |
| Jun 16 | $38.83 | $41.28 | $43.88 | +0.06% |
| Jun 17 | $38.64 | $41.28 | $44.10 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.64 | $41.28 | $44.10 | +0.07% |
| Week 2 | $37.63 | $41.31 | $45.35 | +0.14% |
| Week 3 | $36.87 | $41.34 | $46.34 | +0.21% |
| Week 4 | $36.25 | $41.37 | $47.20 | +0.29% |
| Week 5 | $35.72 | $41.40 | $47.98 | +0.36% |
| Week 6 | $35.24 | $41.43 | $48.69 | +0.43% |
| Week 7 | $34.82 | $41.46 | $49.36 | +0.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Structure Therapeutics Inc. is a clinical stage global biopharmaceutical company that develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs including glucose-dependent insulinotropic polypeptide receptor (GIPR) program and GCG program, which identified multiple hits for small molecule GIPR modulation and GCGR modulation. The company was incorporated in 2016 and is headquartered in South San Francisco, California, and was formerly known as ShouTi Inc.
GPCR is Structure Therapeutics Inc., a healthcare company trading under the symbol GPCR. It currently trades at $39.19 with a market cap of $2.79B and ranks 1783. The stock sits in a near-term context where recent technicals point to a neutral tone, with a 30-day price range roughly from $32.54 to $47.20.
The longer-run forecast shows an upside trajectory beginning in the late 2020s and extending into the 2030s and beyond, with projected average prices climbing from the mid-to-high forties by 2030 and advancing further into the mid-to-high hundreds by 2050. These forecasts imply a path of appreciation from the present level toward higher price targets over the multi-year horizon, though they are not guarantees and carry uncertainty.
A major floor 26.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.0% below — buyers have tended to step in here.
The nearest ceiling, 9.9% above — a clean break opens room to run.
A major ceiling 117.8% above — clearing it would confirm fresh momentum.
Key GPCR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GPCR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $37.82 | Buy | $38.03 | Buy |
| MA 10 | $38.63 | Buy | $38.29 | Buy |
| MA 20 | $38.29 | Buy | $39.16 | Buy |
| MA 50 | $43.88 | Sell | $43.87 | Sell |
| MA 100 | $56.87 | Sell | $48.01 | Sell |
| MA 200 | $47.26 | Sell | $46.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.59 | Neutral |
| Stoch RSI (14) | 76.48 | Neutral |
| CCI (20) | -35.57 | Neutral |
| Williams %R (14) | -55.94 | Info |
| MACD (12,26,9) | 0.38 | Buy |
| ROC (12) | 2.44 | Buy |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 44.06 | Neutral |
| TRIX (15) | -0.67 | Sell |
| Awesome (5,34) | -2.44 | Sell |
| Ultimate (7,14,28) | 40.02 | Neutral |
| Momentum (10) | -1.42 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 37.68 | Buy |
| ADX (14) | 25.97 | Sell |
| ATR (14) | 0.97 | Info |
The 30-day technical picture places the stock in a neutral zone. The RSI14 stands at 40, indicating modest momentum, while the SMA50 is $46.31 and the SMA200 is $46.25. The price has framed a nearby support around $35.88 and a nearby resistance around $54.25.
The 30-day range spans from $32.54 to $47.20, highlighting a relatively tight trading window around the mid-$40s. Overall, near-term momentum is balanced, with no clear tilt toward breakouts or breakdowns.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $35.88 | $41.25 | $52.36 | 0% | Neutral | |
| $31.53 | $39.38 | $51.93 | -5% | Neutral | |
| $31.85 | $40.78 | $55.60 | -1% | Neutral | |
| $34.70 | $45.36 | $63.49 | +10% | Neutral | |
| $36.46 | $48.53 | $69.46 | +18% | Neutral | |
| $37.89 | $51.27 | $74.85 | +24% | Bullish | |
| $37.91 | $52.10 | $77.41 | +26% | Bullish | |
| $37.18 | $51.84 | $78.26 | +26% | Bullish | |
| $36.02 | $50.92 | $78.01 | +23% | Bullish | |
| $36.30 | $52.01 | $80.76 | +26% | Bullish | |
| $45.67 | $69.43 | $114.21 | +68% | Bullish | |
| $78.01 | $131.23 | $234.90 | +218% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| June 2026 | $35.88 | $41.25 | $49.24 | +0.00% |
| July 2026 | $34.70 | $40.87 | $49.36 | -0.92% |
| August 2026 | $35.12 | $41.64 | $50.82 | +1.87% |
| September 2026 | $35.78 | $42.64 | $52.47 | +2.41% |
| October 2026 | $34.98 | $41.88 | $51.92 | -1.78% |
| November 2026 | $34.14 | $41.05 | $51.22 | -1.98% |
| December 2026 | $34.55 | $41.71 | $52.36 | +1.61% |
Click any year to see its month-by-month GPCR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GPCR could reach as high as $52.36, with a base case around $41.25 and support toward $35.88 — roughly 0% from $41.25. A consolidation phase looks the most probable path here.
Expect GPCR to range from $31.53 to $51.93 through 2027. The $39.38 average target implies a -5% move from current prices. That is -5% versus the projected 2026 average. Price action looks broadly range-bound.
The GPCR price prediction for 2028 points to an average of $40.78 (low $31.85, high $55.60) — a potential decline of -1% on today's $41.25. A consolidation phase looks the most probable path here.
In 2029, GPCR is projected to trade between $34.70 and $63.49, averaging $45.36 — a potential gain of +10% from today's $41.25. That is up +11% on the projected 2028 average. Price action looks broadly range-bound.
Structure Therapeutics Inc.'s 2030 outlook centres on $48.53, within a $36.46 to $69.46 range. That is up +7% on the projected 2029 average. That marks a +18% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, GPCR could reach as high as $74.85, with a base case around $51.27 and support toward $37.89 — roughly +24% from $41.25. Momentum favours further upside here.
Expect GPCR to range from $37.91 to $77.41 through 2032. The $52.10 average target implies a +26% move from current prices. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The GPCR price prediction for 2033 points to an average of $51.84 (low $37.18, high $78.26) — a potential gain of +26% on today's $41.25. Momentum favours further upside here.
In 2034, GPCR is projected to trade between $36.02 and $78.01, averaging $50.92 — a potential gain of +23% from today's $41.25. That is -2% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
Structure Therapeutics Inc.'s 2035 outlook centres on $52.01, within a $36.30 to $80.76 range. That is up +2% on the projected 2034 average. That marks a +26% change versus current levels. Momentum favours further upside here.
By 2040, GPCR could reach as high as $114.21, with a base case around $69.43 and support toward $45.67 — roughly +68% from $41.25. Buyers look set to stay in control over this stretch.
Expect GPCR to range from $78.01 to $234.90 through 2050. The $131.23 average target implies a +218% move from current prices. That is up +89% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GPCR today (≈ 24.242424 GPCR) could be worth
$3,181.42
+$2,181.42 (+218%) by 2050 · US Dollar
Based on the average projected GPCR price of $131.23 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GPCRwould be worth at today's price.
$1,000 invested in GPCR on Jun 9, 2025 (≈ 48.756704 GPCR) would be worth
$2,011.21
+$1,011.21 (+101.1%) today · 2.01× · US Dollar
Based on a GPCR entry price of $20.51 vs. today's $41.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $38.55 | $1,070.04 | +7.0% |
| 1 month ago | $39.1 | $1,054.99 | +5.5% |
| 3 months ago | $58.22 | $708.52 | -29.1% |
| 6 months ago | $68.94 | $598.35 | -40.2% |
| 1 year ago | $20.51 | $2,011.21 | +101.1% |
| All time (3.3y) ago | $26 | $1,586.54 | +58.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GPCR forecast.
Our base-case forecast reaches $83.00 around 2050.
Implied market cap at $83.00: $5.9B
The multi-year forecast shows a bullish trajectory beginning in 2030, with the average price projected at $48.44 and a max of $71.15, and a 23.6% implied return in that year. Earlier years show more modest gains, such as 2029 with an average of $46.77 and a 19.3% ROI, and 2027 with an average of $37.33 and a negative ROI of -4.8, reflecting a range of annual outlooks. The 2040 forecast centers around an average of $73.66 with a max of $125.93 and an 88% ROI, while 2050 projects an average of $145.00 with a max of $271.63 and a 270% ROI, all under bullish sentiment.
Drivers and risks hinge on the trajectory of the company’s clinical programs and market dynamics; these figures are estimates and carry uncertainty, not guarantees.
Tap a question to reveal the answer.
2030 forecast shows an average price of $48.44 with a max of $71.15 and an ROI of 23.6, with a bullish sentiment.
Forecasts show neutral sentiment in 2026 with an average of $39.19 and ROI of 0, turning bullish later to 2030 and beyond; these are estimates, not guarantees.
Yes. The 2030 forecast lists a max of $71.15 and an average of $48.44, with a 23.6 ROI and bullish sentiment.
The 2040 forecast shows an average of $73.66, a max of $125.93, and an 88 ROI, with bullish sentiment.
Current price is $39.19 and market cap is $2.79B.
Structure Therapeutics Inc. Community Discussion
0Share your Structure Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.